New sedative trial aims to cut delirium and save lives in elderly ICU patients

NCT ID NCT06251375

Not yet recruiting Disease control Sponsor: St. Joseph's Healthcare Hamilton Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether dexmedetomidine, a sedative that keeps patients more awake and has fewer side effects, can improve survival and reduce confusion in older adults (65+) on breathing machines in the ICU. Researchers will compare it to a placebo (salt water) in 300 patients across multiple hospitals. The goal is to find a safer way to sedate critically ill elderly patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dexmedetomidine
What this could lead to: If it works, this could point toward a safer sedation method for older ICU patients, potentially reducing delirium and improving survival.
What could go wrong: This is a Phase 4 trial with 300 participants, so results may not apply to all ICU patients. The benefit over standard care is uncertain, and sedation risks like low blood pressure or slow heart rate remain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY INSUFFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

respiratory failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESPIRATORY INSUFFICIENCY

Contacts and locations

Locations

Mount Sinai Hospital

Toronto, Ontario, M5G 1X5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.